Ari Green, MD
Dr. Green, Chief of the Division of Neuroinflammation and Glial Biology at the University of California, San Francisco, discusses the development of potential remyelinating therapies and a recent trial of clemastine fumarate in patients with multiple sclerosis and chronic demyelinating optic neuropathy.
Recommended for You
News & Commentary
Quizzes from MD-IQ
Research Summaries from ClinicalEdge
SAN DIEGO—A novel therapy designed to promote the maturation and activation of myelin-producing oligodendrocytes is moving to phase II clinical...
- Does Migraine Transiently Open the Blood–Brain Barrier?
- Is Chronification the Natural History of Migraine?
- MRI Techniques Could Help Distinguish Between MS and Migraine
- Late Thrombectomy Improves Ischemic Stroke Outcomes
- Aspirin Reduces Stroke Risk Associated With Preeclampsia
- High Dose of Novel Compound Shows Promise for Relapsing-Remitting MS
- What Is the Mechanism of Alemtuzumab-Induced Autoimmunity?
- Patients With MS May Not Receive Appropriate Medicines From Primary Care Doctors
- Troubleshooting Gait and Voice Problems After DBS for Parkinson’s Disease
- Conference News Roundup—American College of Cardiology
ECTRIMS/EAN Guideline: Pharmacologic treatment of MS
Physicians’ Travel & Meeting Guide
- A Systematic Approach to Medically Unexplained Symptoms
- Midwest's First Interdisciplinary Pulmonary Embolism Symposium
- The 3 “Rx’s” of Prescribing Controlled Substances: Rules, Regulations, and Risks
- Women's Health Bahamas Cruise
- Clinical Reviews 2017: 28th Annual Family Medicine and Internal Medicine Update